Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

In honor of the Monday morning blues, here is a sleepy Celsius quiz

August 25, 2014 – 6:04 am | Edit Post

Get Started!

In honor of the Monday morning blues, here is a sleepy Celsius quiz

August 25, 2014 – 6:04 am | Edit Post

Get Started!

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]

Scripps Research Institute Announces Interim Leadership

August 25, 2014 – 12:00 am | Edit Post

James Paulson, chair of TSRI’s Department of Cell and Molecular Biology, has been appointed acting president and CEO.